Anika Therapeutics Inc. $ANIK Stock Holdings Lifted by GSA Capital Partners LLP

GSA Capital Partners LLP lifted its holdings in Anika Therapeutics Inc. (NASDAQ:ANIK) by 192.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 122,062 shares of the biotechnology company’s stock after buying an additional 80,319 shares during the quarter. GSA Capital Partners LLP’s holdings in Anika Therapeutics were worth $1,173,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of ANIK. Quarry LP bought a new position in shares of Anika Therapeutics in the 3rd quarter worth about $71,000. CWM LLC lifted its position in Anika Therapeutics by 14.5% in the 4th quarter. CWM LLC now owns 8,537 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 1,080 shares during the last quarter. Occudo Quantitative Strategies LP bought a new stake in Anika Therapeutics in the 3rd quarter valued at about $95,000. Tudor Investment Corp ET AL bought a new stake in Anika Therapeutics in the 3rd quarter valued at about $107,000. Finally, Inscription Capital LLC bought a new stake in Anika Therapeutics in the 4th quarter valued at about $122,000. 91.53% of the stock is currently owned by institutional investors.

Anika Therapeutics Trading Down 0.8%

Anika Therapeutics stock opened at $15.02 on Friday. The stock has a market cap of $199.92 million, a price-to-earnings ratio of -19.01 and a beta of 0.16. The company’s 50-day moving average price is $14.77 and its two-hundred day moving average price is $11.81. Anika Therapeutics Inc. has a 52 week low of $7.87 and a 52 week high of $16.24.

Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of ($0.07) by $0.34. The firm had revenue of $29.61 million for the quarter, compared to analysts’ expectations of $28.14 million. Anika Therapeutics had a negative net margin of 9.52% and a negative return on equity of 5.90%. Research analysts expect that Anika Therapeutics Inc. will post -0.74 earnings per share for the current fiscal year.

Insider Activity

In related news, Director John B. Henneman III bought 5,000 shares of the stock in a transaction on Friday, May 1st. The shares were purchased at an average price of $14.66 per share, with a total value of $73,300.00. Following the purchase, the director owned 54,871 shares in the company, valued at approximately $804,408.86. This represents a 10.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Stephen D. Griffin bought 12,200 shares of the stock in a transaction on Thursday, April 30th. The shares were bought at an average cost of $12.29 per share, for a total transaction of $149,938.00. Following the purchase, the chief executive officer owned 36,163 shares in the company, valued at $444,443.27. This trade represents a 50.91% increase in their position. The SEC filing for this purchase provides additional information. 12.08% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ANIK has been the topic of several recent research reports. Wall Street Zen downgraded shares of Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Barrington Research lifted their price objective on shares of Anika Therapeutics from $16.00 to $17.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Anika Therapeutics has a consensus rating of “Hold” and a consensus target price of $17.00.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.